Yulia E. Ryabukhina

Yulia E. Ryabukhina

Auto-generated profile, based on publicly available information

Yulia E. Ryabukhina

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2024 in MD-Onco
Verified
Journal Article
Open access
PDF file
VGV. E. Gruzdev
V. E. Gruzdev
MAM. A. Anisimov
M. A. Anisimov
YRYu. E. Ryabukhina
Yu. E. Ryabukhina
AOA. V. Oskolkov
A. V. Oskolkov
PZP. A. Zeynalova
P. A. Zeynalova
ЮРЮ. Е. Рябухина
Ю. Е. Рябухина
Therapy of chronic pain syndrome and adequate perioperative pain management during treatment of malignant neoplasms are important problems at the current stage of clinical medicine development. Currently, multimodal pain management is effectively applied through drugs of various pharmacological groups prescribed depending on pain intensity in accordance with a digital rating scale. Associated adverse events as well as impossibility of using peroral or transdermal forms in some cases, limit the use of opioid analgesics. High bioavailability and fast absorption of μ1-opioid receptor agonist tafalgin shown during preclinical studies, relatively favorable safety profile allowed to use this drug in oncological clinic.An experience of using tafalgin in treatment of pain syndrome in patients with malignant tumors at the “Lapino” clinical hospital since 2022 is presented. The effectiveness of the drug is evaluated, and its niche in multimodal pain management is determined.

20 September 2023 in MD-Onco
Verified
Journal Article
Open access
PDF file
YRYu. E. Ryabukhina
Yu. E. Ryabukhina
PZP. A. Zeynalova
P. A. Zeynalova
OTO. L. Timofeeva
O. L. Timofeeva
FAF. M. Abbasbeyli
F. M. Abbasbeyli
TVTimur Valiev
Timur Valiev
ЮРЮ. Е. Рябухина
Ю. Е. Рябухина
Multiple myeloma (MM) is a B-cell lymphoproliferative disorder. Its morphological substrate is plasma cells producing monoclonal immunoglobulin. Monoclonal light chains damage nephrons leading to development of acute kidney failure (AKF) which can be diagnosed at MM onset, recurrence, or progression. Dialysis-dependent kidney failure (DDKF) is associated with worse prognosis and decreased overall survival. Currently, the standard of MM therapy complicated by moderate and severe AKF is programs including bortezomib. According to the results of completed trials, achievement of hematological response plays the main role in AKF resolution, therefore, the use of new highly effective regimens of antitumor drug therapy is recommended. Despite the results of large clinical trials showing the effectiveness of daratumumab in therapy of patients with MM, data on its use in patients with newly diagnosed MM complicated by DDKF who are candidates for autologous hematopoietic stem cell transplant are limited. A case of daratumumab therapy (as monotherapy and in combination with lenalidomide, dexamethasone) of a 38-year-old female patient with MM complicated by DDKF and significant adverse events developed during previous short-term treatment with bortezomib is presented. The achieved hematological response (partial remission, absence of minimal residual disease), satisfactory somatic condition, as well as favorable daratumumab safety profile allowed to consider the patient for autologous hematopoietic stem cell transplant and increased the probability of improved renal response with subsequent cancellation of hemodialysis.

15 August 2023 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
NSNatalja A. Susuleva
Natalja A. Susuleva
YRYulia E. Ryabukhina
Yulia E. Ryabukhina
PZPervin A. Zeynalova
Pervin A. Zeynalova
MSMarina I. Savelyeva
Marina I. Savelyeva
РЕРябухина Юлия Евгеньевна
Рябухина Юлия Евгеньевна
One of the main problems in pediatrics and pediatric oncology is early diagnosis of malignancies in children. It makes a provision for high surveillance more than 90% and ability to restrict an anti-cancer treatment, which define a high quality of life with low incidence of acute reactions and complications of anti-cancer therapy especially delayed. At the same time, even today up to 75% of patients are check into a specialized hospital with advanced disease stages and large tumor mass. The main reason of it is the absence of cancer alterness in first patients contact doctors: pediatricians, highly specialized non-oncological doctors. Identification of high tumor risk children, knowledge of symptoms for differential diagnosis with oncological disorders, abidance by principium of cancer alterness, optimal patients logistics and teamwork of all doctors involved in patients with cancer are the recipe for successful treatment.

10 September 2021 in Oncohematology
Verified
Journal Article
Open access
PDF file
FKF. Sh. Kamolova
F. Sh. Kamolova
AMA. M. Mudunov
A. M. Mudunov
PZP. A. Zeynalova
P. A. Zeynalova
LGL. Yu. Grivtsova
L. Yu. Grivtsova
GAG. F. Allakhverdieva
G. F. Allakhverdieva
ЦЧЦ. Чжао
Ц. Чжао
Background. Lymphomas are a heterogeneous group of the lymphoid and hematopoietic system tumors. Neoplastic process often develops in head and neck area, including the integumentary tissues, orbit, nasal cavity, paranasal sinuses, oral cavity, pharynx, salivary glands, thyroid gland, as well as neck lymph nodes. The difficulties of head and neck lymphomas diagnosis are significant, since very often there is a combined non-tumor pathology. The high heterogeneity of lymphomas in the head and neck area requires structuring knowledge about their epidemiology and clinical manifestations.Objective: to study the epidemiological and clinical features of the head and neck lymphoproliferative diseases, which will lead to an improvement in diagnostic quality of this nosology’s.Materials and methods. The frequency of head and neck lymphoproliferative diseases detection was estimated based on the study of epicrisis and clinical data of 174 patients hospitalized at the N.N. Blokhin National Medical Research Center of Oncology in the period from 2000 to 2020.Results. Taking into account the modern clinical and morphological classification of lymphomas of the World Health Organization (2017), information about the features of localization, characteristic signs of extranodal foci and lymph nodes is presented. Detection frequency of various subtypes non-Hodgkin’s and Hodgkin’s lymphomas were determined on a sufficient cohort of patients.Conclusion. Based on the analysis of clinical and morphological features of head and neck lymphomas, epidemiological and clinical features are described in detail, and differences in the symptoms and clinical manifestations of non-Hodgkin’s and Hodgkin’s lymphomas with a predominant head and neck involvement are revealed.

2 April 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
GRG. A. Radzhabova
G. A. Radzhabova
TVTimur Valiev
Timur Valiev
YRYu. E. Ryabukhina
Yu. E. Ryabukhina
MSM. I. Savelyeva
M. I. Savelyeva
SASherzod Pardaboevich Abdullaev
Sherzod Pardaboevich Abdullaev
ЮРЮ. Е. Рябухина
Ю. Е. Рябухина
Background. A significant advancement in the treatment of high-grade aggressive non-Hodgkin’s lymphomas and acute lymphoblastic leukemia is the inclusion of high-dose (1000–5000 mg/m2) methotrexate in the treatment protocol. This approach has significantly increased the long-term survival rate, but it has been associated with toxicity, requiring supportive care. Factors that predict toxicity were identified, including genes involved in the metabolism (MTHFR) or transport (SLCO1B1) of methotrexate. The analysis of methotrexate metabolism has identified additional genes responsible for the elimination of this drug, allowing for more effective prevention and treatment of methotrexate-associated toxicity.Aim. To study the genetic polymorphisms of enzymes involved in the methotrexate metabolism and associated toxicity in the treatment of pediatric acute lymphoblastic leukemia and non-Hodgkin’s lymphomas.Materials and methods. Data were analyzed in specialized medical databases such as Pubmed, Scopus, Web of Science, Frontiers, and Google Scholar from 2001 to 2024.Results. The main predictors of high-dose methotrexate-associated toxicity are gene polymorphisms in MTHFR, SLCO1B1, ARID5B.Conclusion. Despite the contradictory data presented in the literature, it is important to consider the detection of polymorphisms during high-dose methotrexate treatment in order to administer timely supportive care and prevent significant toxicity.

19 July 2022 in Oncohematology
Verified
Journal Article
Open access
PDF file
YRYu. E. Ryabukhina
Yu. E. Ryabukhina
FAF. M. Abbasbeyli
F. M. Abbasbeyli
PZP. A. Zeynalova
P. A. Zeynalova
OTO. L. Timofeeva
O. L. Timofeeva
ABA. F. Batsev
A. F. Batsev
ЮРЮ. Е. Рябухина
Ю. Е. Рябухина
Follicular lymphoma is a tumor of mature B-lymphocytes, characterized by a predominantly indolent course. Despite advances in first-line therapy, disease relapses still occur, and with an increase in the follow-up period, the risk of transformation into diffuse large B-cell lymphoma also increases. The choice of a further anticancer therapy is based on the results of a comprehensive examination and repeated biopsy. In addition, previous remission duration, previous treatment, clinical manifestation of relapse, the patient's somatic condition and comorbidity are taken into account. A clinical observation of a 57-year-old patient with relapsed follicular lymphoma, who received various chemotherapy regimens in combination with rituximab in the 1st and subsequent lines, is presented. After repeated biopsy and exclusion of transformation into diffuse large B-cell lymphoma, the patient received lenalidomide therapy in combination with obinutuzumab. A partial antitumor response after 4 cycles with decrease in tumor volume by more than 80 % by the end of induction was achieved. The absence of severe adverse events, together with a pronounced antitumor effect, significantly improved the patient's quality of life.